How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns-Reference-Cited by-同舟云学术

How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns

Published:2019-08-01 Issue:5 Volume:134 Page:415-420
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Mazepa Marshall A.¹^ORCID,Masias Camila²,Chaturvedi Shruti³^ORCID

Affiliation:

1. Department of Medicine, University of Minnesota, Minneapolis, MN;

2. Division of Hematology, Department of Medicine, Ohio State University, Columbus, OH; and

3. Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Abstract

Abstract Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor–platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/5/415/1554088/bloodbld2019000954c.pdf

Reference40 articles.

1. Thrombotic thrombocytopenic purpura;Joly;Blood,2017

2. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura;Rock;N Engl J Med,1991

3. Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story;Froissart;Eur J Intern Med,2015

4. Caplacizumab for acquired thrombotic thrombocytopenic purpura;Peyvandi;N Engl J Med,2016

5. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura;Scully;N Engl J Med,2019

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematologic and lymphoid abnormalities in SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

3. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons;Expert Review of Hematology;2024-02-20

4. Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura;BLOOD TRANSFUS-ITALY;2023

5. A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura;Blood Advances;2023-08-28